Cancer Research · 2008 · 105 citations · 40 references
MedicineMolecular BiologyOncologyMolecular OncologyOncogenesTranscriptional RegulationCervical CancerCervical LesionsEpigenetic Regulation In CancerPolycomb RegulationViral OncogenesViral OncogenesisApoptotic Resistance MechanismsE7 ExpressionE7 OncoproteinHpv OncogenesisHuman Papillomavirus (Hpv) OncogenesisHuman Papillomavirus OncogenesisPolycomb Group ProteinsPolycomb Group Regulation
The malignant phenotype of human papillomavirus (HPV)-positive cancer cells is maintained by the activity of the viral E6 and E7 genes. Here, we identified the polycomb group gene enhancer of zeste homologue 2 (EZH2) as a novel downstream target for the viral oncogenes in HPV-transformed cells. EZH2 expression was activated by HPV16 E7 at the transcriptional level via E7-mediated release of E2F from pocket proteins. RNA interference analyses showed that continuous EZH2 expression is required for the proliferation of HPV-positive tumor cells by stimulating cell cycle progression at the G1-S boundary. In addition to its growth-promoting activity, EZH2 also contributed to the apoptotic resistance of cervical cancer cells. Furthermore, we found that HPV-positive dysplastic and tumorigenic cervical lesions were characterized by high levels of EZH2 protein in vivo. We conclude that the E7 target gene EZH2 is a major determinant for the proliferation of HPV-positive cancer cells and contributes to their apoptotic resistance. Moreover, EZH2 may serve as a novel therapeutic target for the treatment of cervical cancer.
40
WAF1, a potential mediator of p53 tumor suppression
Wafik S. El‐Deiry, Takashi Tokino, Victor E. Velculescu et al. · Cell · 1993 · 8.4K citations
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Ru Cao, Liangjun Wang, Hengbin Wang et al. · Science · 2002 · 3.8K citations